wellness

The state of being in great health, and continually striving to attain all of your goals.

Huntington’s Disease Treatment Market Size and Forecast 2025: A New Era of Hope for a Rare Genetic Disorder. AI-Generated.
Global Huntington’s Disease Treatment Market Overview The global Huntington’s disease (HD) treatment market is entering a transformative phase, driven by rapid advances in biotechnology, rising disease awareness, and a growing commitment from pharmaceutical companies to tackle rare and complex neurological disorders. Huntington’s disease is a hereditary, progressive neurodegenerative condition characterized by motor dysfunction, cognitive decline, and psychiatric disturbances. Although there is still no cure, the treatment landscape is evolving quickly, shifting from purely symptom management toward more targeted and potentially disease-modifying approaches.
By Gita Mam17 days ago in Longevity
The Mathematics of Resilience
Most days, health slips by unnoticed. Life moves forward, tasks get done, rest happens - all while the body runs quietly beneath it. Without pain or warning, people tend to accept wellness at face value. Yet once discomfort arrives, everything shifts. A single sign can shatter the calm. Only then does awareness rise.
By Dr Marc Nock, DDS18 days ago in Longevity
The 5 Things People Over 70 Regret With Their Health
But recently I started asking a different question. Instead of studying what fit older people do right, I asked what they wish they'd done differently.
By Destiny S. Harris18 days ago in Longevity
Daily consumption of coffee or tea may lower the risk of dementia, according to researchers.
Daily consumption of two to three cups of caffeinated coffee or one to two cups of tea may be associated with a lower risk of developing dementia later in life, as well as the potential to slow the progression of cognitive decline, according to new research. While the findings have excited both tea and coffee lovers, scientists stress that the results show correlation rather than definitive proof of cause and effect — and that a healthy lifestyle overall remains vital for brain health.
By Raviha Imran18 days ago in Longevity
Pulmonary Embolism: Symptoms, Causes, Treatment, and Prevention of a Silent Killer
Introduction Pulmonary embolism (PE) is a serious, potentially life-threatening condition that occurs when a blood clot blocks one or more arteries in the lungs. It is one of the most critical emergencies in cardiovascular health, ranking just after heart attacks and strokes in terms of morbidity and mortality. PE often originates from deep vein thrombosis (DVT), a blood clot in the veins of the legs or pelvis, that travels through the bloodstream to the lungs. Understanding the risk factors, early symptoms, diagnostic methods, treatment options, and preventive strategies is essential to improving outcomes and saving lives.
By Story Prism18 days ago in Longevity
The First Step Toward True Health
Have you noticed how horribly sick everyone is these days? Over 75% of people have one chronic health disease... 50% have two or more...
By Dr. Cody Dakota Wooten, DFM, DHM, DAS (hc)19 days ago in Longevity
The Healthiest People I Know Do Less Than You Think. Here's Their Actual Routine.
Two-hour gym sessions. Strict meal plans. Supplements lined up on the counter. A level of discipline that bordered on obsession.
By Destiny S. Harris19 days ago in Longevity
Novo Nordisk Sues Hims & Hers Over Cheaper Copycat Wegovy Pills and Injections. AI-Generated.
In a significant legal development in the pharmaceutical industry, Novo Nordisk, the maker of the popular weight loss drug Wegovy, has filed a lawsuit against Hims & Hers Health Inc., accusing the company of producing and selling cheaper, copycat versions of Wegovy’s pills and injections. The lawsuit, which has raised concerns about intellectual property rights, competition, and the future of weight loss treatments, has sent shockwaves through the healthcare market.
By Ayesha Lashari19 days ago in Longevity
Why More and More Seniors Are Spending Time at McDonald’s
It only takes a few minutes sitting inside a McDonald’s, at almost any time of day, to notice a quiet but meaningful phenomenon. Elderly people are there. Sometimes alone, sometimes in pairs, sometimes simply seated with a coffee or a barely touched tray. They take their time. They observe. They watch life move around them. Nothing dramatic. Nothing noisy. And yet, their presence speaks volumes.
By Bubble Chill Media 19 days ago in Longevity
Discovering the Unexpected Serenity of Walking Meditations
“I found that one of the hardest things about mindfulness practice was to let go of effort. For years, I treated meditation as one more item on my daily to-do list — mindfulness…check. This task orientation turned meditation into a chore that I could do incorrectly.” — Seth J. Gillihan, PhD, Mindful Cognitive Behavioral Therapy: A Simple Path to Healing, Hope, and Peace
By Leigh Victoria Phan, MS, MFA19 days ago in Longevity
Novo Nordisk Sues Hims & Hers Over Cheaper Copycat Wegovy Pills and Injections. AI-Generated.
If you’ve been following the weight-loss drug boom, you’ve probably heard of Wegovy, the blockbuster injection from Novo Nordisk. But recently, the story took a dramatic twist: Novo Nordisk is suing Hims & Hers, the popular telehealth company, over cheaper, copycat versions of the drug. Here’s everything you need to know about this high-stakes legal clash and what it means for patients, telehealth companies, and the pharmaceutical industry. What Happened? Novo Nordisk, the Danish pharmaceutical giant behind Wegovy, has filed a patent infringement lawsuit against Hims & Hers in a Delaware federal court. The lawsuit claims that Hims & Hers marketed unapproved, compounded versions of semaglutide — Wegovy’s active ingredient — as cheaper alternatives to the brand-name drug. According to Novo Nordisk, Hims & Hers’ actions not only infringe on its patents but also bypass important safety regulations. The pharmaceutical company is asking the court to issue a permanent injunction to stop Hims & Hers from selling these products and is seeking damages for lost profits. Why Wegovy Matters Wegovy isn’t just another weight-loss medication — it’s one of Novo Nordisk’s most profitable and fastest-growing products. It works by using GLP-1 technology, which helps regulate appetite and glucose levels. The drug’s success has made it a key part of the global weight-loss and diabetes market, with competitors like Eli Lilly racing to develop similar treatments. With prices for Wegovy often reaching several hundred dollars per month, the market for cheaper alternatives is huge. That’s where Hims & Hers saw an opportunity — but it may have crossed a legal line. What Hims & Hers Did Hims & Hers, best known for online prescriptions and telehealth services, briefly offered a compounded semaglutide pill for as low as $49 for the first month. Compounded drugs are made by pharmacies by mixing ingredients to meet specific patient needs. While compounding is legal in some cases, it doesn’t require FDA approval in the same way as branded drugs. That means quality, dosage, and safety can vary significantly. Novo Nordisk argues that Hims & Hers went beyond legal compounding rules by mass-marketing unapproved semaglutide products that directly compete with Wegovy. Within days of launching the pill, Hims & Hers pulled it from the market, citing regulatory pressure and discussions with the FDA. Despite this, Novo Nordisk says other forms, including injectable versions of the compounded drug, are still being offered, prompting the lawsuit. Legal and Regulatory Stakes The case highlights the tension between drug safety, patent protection, and affordability. Novo Nordisk holds semaglutide patents until the early 2030s, covering both oral and injectable versions. The company argues that protecting these patents ensures patients receive medications that are safe, tested, and effective. For Hims & Hers, the case raises questions about patient access to lower-cost medications. Telehealth companies have grown rapidly during the pandemic by offering convenient, direct-to-consumer treatments. Some argue that compounded drugs can make high-cost medications more accessible — but the trade-off can be safety and regulatory compliance. The FDA has warned that unapproved weight-loss drug copies could pose risks to patients, citing potential inconsistencies in dosing and quality. This regulatory scrutiny adds another layer to the legal battle. Market and Investor Impact The news of the lawsuit has already affected the stock market. Hims & Hers’ shares dropped, while Novo Nordisk’s stock rose, signaling investor confidence in the company’s move to defend its drug patents. Analysts are closely watching this case as an indicator of how the growing GLP-1 weight-loss market will handle competition and pricing pressure. Some experts believe this lawsuit is part of a broader trend where big pharma pushes back against low-cost competitors. Others argue it highlights the ongoing debate over access to affordable treatments versus innovation and safety. What This Means for Patients For patients, this legal battle is a reminder of the risks and rewards of new weight-loss treatments. On one hand, cheaper alternatives can make medications like semaglutide more accessible. On the other, unapproved compounded drugs may not meet the same safety standards as FDA-approved options. Anyone considering weight-loss drugs should consult a licensed healthcare provider and carefully weigh the pros and cons of brand-name versus compounded medications. The Road Ahead The lawsuit will likely play out over months, possibly even years. Novo Nordisk is committed to defending its patents and challenging unapproved competition, while Hims & Hers may argue for affordability and patient access. Regulatory agencies, particularly the FDA, will continue to play a crucial role in determining what’s allowed in the fast-growing telehealth and weight-loss market. For now, patients and investors alike are keeping a close eye on this legal showdown — a case that could shape the future of obesity drugs in the U.S. Key Takeaways Novo Nordisk sues Hims & Hers for selling unapproved semaglutide alternatives. The dispute centers on patent infringement and drug safety concerns. Compounded drugs are cheaper but not FDA-approved and can vary in quality. The outcome could affect the booming GLP-1 weight-loss market and telehealth business models. This case is more than a legal fight; it’s a clash between innovation, accessibility, and regulation — and the stakes couldn’t be higher for patients, companies, and investors in the rapidly expanding weight-loss drug industry.
By Abid Ali19 days ago in Longevity
Wellness for Therapists: Small Adjustments That Make a Big Difference
The good news? Improving your well-being doesn’t require a dramatic life overhaul. Sometimes, small tweaks in your routine, environment, or mindset can lead to big shifts in how you feel and function. Below are some practical, easy-to-implement ideas designed specifically for therapists who want to feel better, work smarter, and bring more joy into their daily grind.
By Vala Flynn19 days ago in Longevity